1. Home
  2. EDIT vs VXRT Comparison

EDIT vs VXRT Comparison

Compare EDIT & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • VXRT
  • Stock Information
  • Founded
  • EDIT 2013
  • VXRT N/A
  • Country
  • EDIT United States
  • VXRT United States
  • Employees
  • EDIT N/A
  • VXRT N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • VXRT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EDIT Health Care
  • VXRT Health Care
  • Exchange
  • EDIT Nasdaq
  • VXRT Nasdaq
  • Market Cap
  • EDIT 176.7M
  • VXRT 200.3M
  • IPO Year
  • EDIT 2016
  • VXRT N/A
  • Fundamental
  • Price
  • EDIT $1.32
  • VXRT $0.61
  • Analyst Decision
  • EDIT Buy
  • VXRT Strong Buy
  • Analyst Count
  • EDIT 14
  • VXRT 2
  • Target Price
  • EDIT $8.08
  • VXRT $3.00
  • AVG Volume (30 Days)
  • EDIT 3.3M
  • VXRT 1.4M
  • Earning Date
  • EDIT 11-04-2024
  • VXRT 11-13-2024
  • Dividend Yield
  • EDIT N/A
  • VXRT N/A
  • EPS Growth
  • EDIT N/A
  • VXRT N/A
  • EPS
  • EDIT N/A
  • VXRT N/A
  • Revenue
  • EDIT $61,759,000.00
  • VXRT $16,760,000.00
  • Revenue This Year
  • EDIT N/A
  • VXRT $128.43
  • Revenue Next Year
  • EDIT N/A
  • VXRT N/A
  • P/E Ratio
  • EDIT N/A
  • VXRT N/A
  • Revenue Growth
  • EDIT 150.95
  • VXRT 303.27
  • 52 Week Low
  • EDIT $1.28
  • VXRT $0.52
  • 52 Week High
  • EDIT $11.58
  • VXRT $1.54
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 24.88
  • VXRT 46.20
  • Support Level
  • EDIT $1.28
  • VXRT $0.53
  • Resistance Level
  • EDIT $2.37
  • VXRT $0.63
  • Average True Range (ATR)
  • EDIT 0.18
  • VXRT 0.05
  • MACD
  • EDIT -0.04
  • VXRT 0.00
  • Stochastic Oscillator
  • EDIT 6.45
  • VXRT 43.69

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About VXRT Vaxart Inc

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Share on Social Networks: